NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category (Descending) | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
16714-0159-01 | 16714-0159 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | April 6, 2021 | In Use | |
00904-7144-61 | 00904-7144 | Dronabinol | Dronabinol | 2.5 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | March 3, 2021 | In Use | |
00904-7145-04 | 00904-7145 | Dronabinol | Dronabinol | 5.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | March 3, 2021 | In Use | |
16714-0160-01 | 16714-0160 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | April 6, 2021 | In Use | |
16714-0200-30 | 16714-0200 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | April 27, 2021 | In Use | |
16714-0201-10 | 16714-0201 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | April 27, 2021 | In Use | |
16714-0201-30 | 16714-0201 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | April 27, 2021 | In Use | |
42806-0358-01 | 42806-0358 | Leucovorin Calcium | Leucovorin Calcium | 5.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | April 16, 2020 | In Use | |
42806-0358-30 | 42806-0358 | Leucovorin Calcium | Leucovorin Calcium | 5.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | April 16, 2020 | In Use | |
72865-0140-30 | 72865-0140 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | March 9, 2020 | In Use | |
72865-0140-90 | 72865-0140 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | March 9, 2020 | In Use | |
72578-0019-06 | 72578-0019 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | April 15, 2019 | In Use | |
72578-0019-16 | 72578-0019 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | April 15, 2019 | In Use | |
70518-0397-00 | 70518-0397 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | April 4, 2017 | In Use | |
70518-0397-01 | 70518-0397 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | April 4, 2017 | In Use | |
70518-0397-02 | 70518-0397 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | May 11, 2018 | In Use | |
69539-0181-01 | 69539-0181 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Feb. 10, 2020 | In Use | |
72205-0054-01 | 72205-0054 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | May 12, 2020 | In Use | |
69539-0034-01 | 69539-0034 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Sept. 5, 2019 | In Use | |
50742-0181-01 | 50742-0181 | Leucovorin Calcium | Leucovorin Calcium | 5.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | July 30, 2020 | In Use | |
50742-0181-30 | 50742-0181 | Leucovorin Calcium | Leucovorin Calcium | 5.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | July 30, 2020 | In Use | |
50742-0182-12 | 50742-0182 | Leucovorin Calcium | Leucovorin Calcium | 10.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | July 30, 2020 | In Use | |
50742-0182-24 | 50742-0182 | Leucovorin Calcium | Leucovorin Calcium | 10.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | July 30, 2020 | In Use | |
72266-0124-01 | 72266-0124 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | April 2, 2019 | In Use | |
72266-0124-10 | 72266-0124 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | April 2, 2019 | In Use | |
71930-0018-30 | 71930-0018 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 11, 2018 | In Use | |
71930-0018-52 | 71930-0018 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 6, 2020 | In Use | |
71930-0017-30 | 71930-0017 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 11, 2018 | In Use | |
71930-0017-52 | 71930-0017 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 6, 2020 | In Use | |
60687-0252-40 | 60687-0252 | Ondansetron | Ondansetron | 4.0 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 7, 2019 | In Use | |
60687-0252-46 | 60687-0252 | Ondansetron | Ondansetron | 4.0 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 7, 2019 | In Use | |
60687-0252-67 | 60687-0252 | Ondansetron | Ondansetron | 4.0 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 11, 2019 | May 31, 2019 | In Use |
60687-0252-86 | 60687-0252 | Ondansetron | Ondansetron | 4.0 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 7, 2019 | In Use | |
63187-0266-10 | 63187-0266 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov. 3, 2014 | In Use | |
63187-0266-15 | 63187-0266 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | June 1, 2018 | In Use | |
63187-0266-20 | 63187-0266 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 1, 2017 | In Use | |
63187-0266-30 | 63187-0266 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov. 3, 2014 | In Use | |
42806-0359-25 | 42806-0359 | Leucovorin Calcium | Leucovorin Calcium | 25.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | April 16, 2020 | In Use | |
50742-0183-24 | 50742-0183 | Leucovorin Calcium | Leucovorin Calcium | 15.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | July 30, 2020 | In Use | |
50742-0184-25 | 50742-0184 | Leucovorin Calcium | Leucovorin Calcium | 25.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | July 30, 2020 | In Use | |
60687-0428-01 | 60687-0428 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Aug. 26, 2019 | In Use | |
60687-0428-65 | 60687-0428 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Jan. 20, 2020 | In Use | |
68001-0437-25 | 68001-0437 | Zoledronic acid | Zoledronic acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | June 29, 2020 | In Use | ||
00074-6463-32 | 00074-6463 | Cyclosporine Modified | Gengraf | 25.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | May 24, 2010 | Aug. 31, 2017 | No Longer Used |
00074-6479-32 | 00074-6479 | Cyclosporine Modified | Gengraf | 100.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | May 24, 2010 | Sept. 16, 2017 | No Longer Used |
00093-0233-19 | 00093-0233 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 16, 2009 | Oct. 31, 2015 | No Longer Used | |
00093-0233-33 | 00093-0233 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 3, 2007 | Jan. 31, 2015 | No Longer Used | |
00093-0233-56 | 00093-0233 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 3, 2007 | Oct. 31, 2015 | No Longer Used | |
00093-0233-93 | 00093-0233 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct. 21, 2010 | Aug. 31, 2013 | No Longer Used | |
00093-7236-19 | 00093-7236 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 16, 2009 | July 31, 2016 | No Longer Used |
00093-7236-33 | 00093-7236 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 3, 2007 | Jan. 31, 2014 | No Longer Used |
00093-7236-56 | 00093-7236 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 3, 2007 | July 31, 2016 | No Longer Used |
00093-7236-93 | 00093-7236 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 14, 2010 | Jan. 31, 2014 | No Longer Used |
00093-7301-19 | 00093-7301 | Ondansetron | Ondansetron | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 23, 2010 | Jan. 13, 2013 | No Longer Used | |
00093-7301-56 | 00093-7301 | Ondansetron | Ondansetron | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 3, 2007 | Feb. 23, 2010 | No Longer Used | |
00093-7301-65 | 00093-7301 | Ondansetron | Ondansetron | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 23, 2010 | Jan. 13, 2013 | No Longer Used | |
00093-7302-03 | 00093-7302 | Ondansetron | Ondansetron | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 23, 2010 | Nov. 30, 2012 | No Longer Used | |
00093-7302-19 | 00093-7302 | Ondansetron | Ondansetron | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 23, 2010 | Nov. 30, 2012 | No Longer Used | |
00093-7302-35 | 00093-7302 | Ondansetron | Ondansetron | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 3, 2007 | Feb. 23, 2010 | No Longer Used | |
00093-7302-56 | 00093-7302 | Ondansetron | Ondansetron | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 3, 2007 | Feb. 23, 2010 | No Longer Used | |
00093-7302-65 | 00093-7302 | Ondansetron | Ondansetron | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 23, 2010 | Nov. 30, 2012 | No Longer Used | |
00093-7355-01 | 00093-7355 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Dec. 15, 2006 | Aug. 5, 2013 | In Use |
00093-7355-05 | 00093-7355 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | March 14, 2008 | In Use | |
00093-7355-56 | 00093-7355 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Dec. 15, 2006 | In Use | |
00093-7355-98 | 00093-7355 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Feb. 22, 2007 | In Use | |
00172-7310-00 | 00172-7310 | Cyclosporine Modified | Cyclosporine Modified | 25.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | March 29, 2005 | March 31, 2017 | No Longer Used |
00172-7310-46 | 00172-7310 | Cyclosporine Modified | Cyclosporine Modified | 25.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | March 29, 2005 | March 31, 2017 | No Longer Used |
00172-7311-00 | 00172-7311 | Cyclosporine Modified | Cyclosporine Modified | 50.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | April 28, 2005 | Feb. 28, 2017 | No Longer Used |
00172-7311-46 | 00172-7311 | Cyclosporine Modified | Cyclosporine Modified | 50.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | April 28, 2005 | Feb. 28, 2017 | No Longer Used |
00172-7312-00 | 00172-7312 | Cyclosporine Modified | Cyclosporine Modified | 100.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | March 29, 2005 | March 31, 2017 | No Longer Used |
00172-7312-46 | 00172-7312 | Cyclosporine Modified | Cyclosporine Modified | 100.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | March 29, 2005 | March 31, 2017 | No Longer Used |
00378-1003-39 | 00378-1003 | Granisetron Hydrochloride | Granisetron Hydrochloride | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 30, 2008 | April 12, 2010 | No Longer Used | |
00378-1003-90 | 00378-1003 | Granisetron Hydrochloride | Granisetron Hydrochloride | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 30, 2008 | April 12, 2010 | No Longer Used | |
00378-1003-94 | 00378-1003 | Granisetron Hydrochloride | Granisetron Hydrochloride | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 30, 2008 | Nov. 30, 2012 | No Longer Used | |
00378-3151-01 | 00378-3151 | Finasteride | Finasteride | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | May 1, 2007 | Nov. 4, 2015 | No Longer Used | |
00378-3151-05 | 00378-3151 | Finasteride | Finasteride | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | July 30, 2010 | Feb. 4, 2011 | No Longer Used | |
00378-3151-77 | 00378-3151 | Finasteride | Finasteride | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | May 1, 2007 | Nov. 4, 2015 | No Longer Used | |
00378-3151-93 | 00378-3151 | Finasteride | Finasteride | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | May 1, 2007 | Nov. 4, 2015 | No Longer Used | |
00378-6868-01 | 00378-6868 | Anagrelide Hydrochloride | Anagrelide Hydrochloride | Ancillary Therapy | Platelet-Reducing Agent | PDE-3 Inhibitor | Oral | Feb. 28, 2011 | Oct. 29, 2010 | No Longer Used | |
00378-6868-05 | 00378-6868 | Anagrelide Hydrochloride | Anagrelide Hydrochloride | Ancillary Therapy | Platelet-Reducing Agent | PDE-3 Inhibitor | Oral | Feb. 28, 2011 | Jan. 31, 2014 | No Longer Used | |
00378-6869-01 | 00378-6869 | Anagrelide Hydrochloride | Anagrelide Hydrochloride | Ancillary Therapy | Platelet-Reducing Agent | PDE-3 Inhibitor | Oral | Feb. 28, 2011 | March 4, 2011 | No Longer Used | |
00378-6869-05 | 00378-6869 | Anagrelide Hydrochloride | Anagrelide Hydrochloride | Ancillary Therapy | Platelet-Reducing Agent | PDE-3 Inhibitor | Oral | Feb. 28, 2011 | Jan. 31, 2014 | No Longer Used | |
00781-3010-72 | 00781-3010 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | June 27, 2007 | March 31, 2017 | No Longer Used |
00781-3010-95 | 00781-3010 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | June 27, 2007 | March 31, 2017 | No Longer Used |
10019-0906-03 | 10019-0906 | Ondansetron | Ondansetron | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Nov. 19, 2010 | July 31, 2013 | No Longer Used | |
10019-0906-04 | 10019-0906 | Ondansetron | Ondansetron | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Nov. 19, 2010 | July 31, 2011 | No Longer Used | |
10019-0906-05 | 10019-0906 | Ondansetron | Ondansetron | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Nov. 19, 2010 | July 31, 2011 | No Longer Used | |
10019-0906-63 | 10019-0906 | Ondansetron | Ondansetron | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Nov. 19, 2010 | July 31, 2013 | No Longer Used | |
16714-0522-01 | 16714-0522 | Finasteride | Finasteride | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | March 4, 2011 | Feb. 28, 2015 | No Longer Used | |
16714-0522-02 | 16714-0522 | Finasteride | Finasteride | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | March 2, 2011 | March 4, 2011 | No Longer Used | |
16714-0522-03 | 16714-0522 | Finasteride | Finasteride | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | March 2, 2011 | Feb. 28, 2015 | No Longer Used | |
16714-0522-04 | 16714-0522 | Finasteride | Finasteride | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | March 2, 2011 | Feb. 28, 2015 | No Longer Used | |
16714-0522-05 | 16714-0522 | Finasteride | Finasteride | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | March 4, 2011 | Feb. 28, 2015 | No Longer Used | |
16714-0522-10 | 16714-0522 | Finasteride | Finasteride | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Sept. 19, 2012 | Aug. 31, 2014 | No Longer Used | |
36000-0012-05 | 36000-0012 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | March 13, 2013 | May 10, 2013 | No Longer Used |
36000-0012-25 | 36000-0012 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | March 13, 2013 | No Longer Used | |
00069-0291-01 | 00069-0291 | filgrastim-aafi | Nivestym | 300.0 ug/.5mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Sept. 24, 2018 | In Use | |
00069-0291-10 | 00069-0291 | filgrastim-aafi | Nivestym | 300.0 ug/.5mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Sept. 24, 2018 | In Use | |
00069-0292-01 | 00069-0292 | filgrastim-aafi | Nivestym | 480.0 ug/.8mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Sept. 24, 2018 | In Use | |
00069-0292-10 | 00069-0292 | filgrastim-aafi | Nivestym | 480.0 ug/.8mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Sept. 24, 2018 | In Use |
Found 10,000 results in 9 milliseconds — Export these results